Annual Report

The report describes the company's transition from a development-stage organization to a commercial enterprise following the U.S. launch of PancreaSure in September 2025. By year-end, twelve high-risk surveillance centers had implemented the test, while five clinical studies were published and CAP accreditation was received for the North Carolina laboratory.